Once-Daily Samsca Increases Serum Sodium Levels
Through Increase in Free Water Clearance.
 

Safety Profile for Samsca

Safety evaluated in >4000 patients in total clinical trials [PI/p2/Section 6.1/par3]

  • Approximately 650 of these patients had hyponatremia, of whom approximately 219 received Samsca for 6 months or more

[PI/p2/Section 6.1/Table 1]

Adverse reactions in Samsca-treated patients

Discontinuation due to adverse reactions similar to placebo

  • In these trials, 10% (23/223) of patients treated with Samsca discontinued treatment because of an adverse reaction compared with 12% (26/220) of patients treated with placebo [PI/p2/Section 6.1/par4]

Preserves electrolytes with no clinically significant impact on renal function1,2 [Konstam/p1325/col2/par2, col3/par1, p1326/col1/par1; DOF/Section 4.2.2.2/par 4-5]

  • No significant change in urine excretion of Na+ and K+ [PI/p3/Section 12.1/par1; p4/Section 12.3/par2]
  • No significant change in BUN or serum creatinine1 [DOF/Section 4.2.2.2/par4,5]
  • Exposure and response to Samsca are similar in patients with creatinine clearance 10-79 mL/min and in patients without renal impairment [PI/p3/Section 8.7/par1, p2/Section 2.3/par1]
    • Samsca has not been evaluated in patients with creatinine clearance <10 mL/min or in patients undergoing dialysis

Read more about:

References:

  1. Konstam MA, Gheorghiade M, Burnett JC Jr, et al; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297(12):1319-1331.
  2. Data on file. Otsuka America Pharmaceutical, Inc.


INDICATION and IMPORTANT SAFETY INFORMATION for SAMSCA® (tolvaptan)


INDICATION

SAMSCA is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium < 125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure, cirrhosis, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH).

Important Limitations

  • Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with SAMSCA.
  • It has not been established that raising serum sodium with SAMSCA provides a symptomatic benefit to patients.

IMPORTANT SAFETY INFORMATION

SAMSCA should be initiated and re-initiated in patients only in a hospital where serum sodium can be monitored closely. Too rapid correction of hyponatremia (e.g., > 12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma and death. In susceptible patients, including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable.

SAMSCA is contraindicated in the following conditions:

  • – Urgent need to raise serum sodium acutely
  • – Inability of the patient to sense or appropriately respond to thirst
  • – Hypovolemic hyponatremia
  • – Concomitant use of strong CYP 3A inhibitors
  • – Anuric patients
  • Too Rapid Correction of Serum Sodium Can Cause Serious Neurologic Sequelae – During initiation and after titration monitor patients to assess serum sodium concentrations and neurologic status. Subjects with SIADH or very low baseline serum sodium concentrations may be at greater risk for too-rapid correction of serum sodium. In patients receiving SAMSCA who develop too rapid a rise in serum sodium, discontinue or interrupt treatment with SAMSCA and consider administration of hypotonic fluid. Fluid restriction during the first 24 hours with SAMSCA may increase the likelihood of overly-rapid correction of serum sodium, and should generally be avoided
  • Gastrointestinal Bleeding in Patients with Cirrhosis – Use in cirrhotic patients only when need to treat outweighs this risk
  • Dehydration and Hypovolemia – In patients who develop medically significant signs or symptoms of hypovolemia, discontinuation is recommended. Dehydration and hypovolemia can occur, especially in potentially volume-depleted patients receiving diuretics or those who are fluid restricted
  • Co-administration with Hypertonic Saline – Not recommended
  • Other Drugs Affecting Exposure to SAMSCA
    • – CYP 3A Inhibitors – Do not use with strong inhibitors of CYP 3A; avoid concomitant use with moderate CYP 3A inhibitors
    • – CYP 3A Inducers – Avoid concomitant use with CYP 3A inducers. If co-administered, the dose of SAMSCA may need to be increased
    • – P-gp Inhibitors – The dose of SAMSCA may have to be reduced if co-administered with P-gp inhibitors
  • Hyperkalemia or Drugs that Increase Serum Potassium – Monitor serum potassium levels in patients with a serum potassium > 5 mEq/L and in patients receiving drugs known to increase serum potassium levels

Pregnancy and Nursing Mothers – SAMSCA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Because many drugs are excreted into human milk and because of the potential for serious adverse reactions in nursing infants from SAMSCA, a decision should be made to discontinue nursing or SAMSCA, taking into consideration the importance of SAMSCA to the mother.

Commonly observed adverse reactions – (SAMSCA incidence ≥ 5% more than placebo, respectively): thirst (16% vs 5%), dry mouth (13% vs 4%), asthenia (9% vs 4%), constipation (7% vs 2%), pollakiuria or polyuria (11% vs 3%) and hyperglycemia (6% vs 1%).

Please see U.S. FULL PRESCRIBING INFORMATION, including Boxed WARNING, and Medication Guide.